Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Pacira Pharmaceuticals

Share:
Related PCRX
Mid-Afternoon Market Update: AZZ Drops On Weak Q3 Results; Stemline Shares Spike Higher
15 Biggest Mid-Day Gainers For Friday

In a report published Friday, Jefferies & Company reiterated its Buy rating on Pacira Pharmaceuticals (NASDAQ: PCRX), and raised its price target from $22.00 to $24.00.

Jefferies noted, “PCRX completed a strong round of financing ($110M ‘convert' at favorable terms) removing a financing overhang – we had modeled cash needs in '13 – and provides a clear runway to profitability in '14. Q4 pre-announced Exparel sales beat estimates and the Exparel commercial metrics bode very well and support our bullish sales estimates. We raise our PT to $24 based on Exparel trends and removal of financing risk.”

Pacira Pharmaceuticals closed on Thursday at $19.43.

Latest Ratings for PCRX

DateFirmActionFromTo
Jan 2017H.C. WainwrightInitiates Coverage OnBuy
Dec 2016Janney CapitalInitiates Coverage OnNeutral
Dec 2016Goldman SachsInitiates Coverage OnBuyNeutral

View More Analyst Ratings for PCRX
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (PCRX)

View Comments and Join the Discussion!